학술논문
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Document Type
Article
Author
Source
Subject
*LYMPHOBLASTIC leukemia
*ACUTE leukemia
*ISOCITRATE dehydrogenase
*PROTEIN-tyrosine kinases
*
*
*
Language
ISSN
0007-1048
Abstract
Summary: Data regarding the use of FMS‐like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3‐ or IDH1/2‐mutated ALL. Three early T‐cell precursor‐ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2 maintained a CR for 27 months after treatment with enasidenib for relapsed disease. Patient 3 was treated with venetoclax and gilteritinib at the time of relapse and maintained a CR with gilteritinib for 8 months. These cases suggest that FLT3 and IDH inhibitors could represent a viable therapeutic option for ALL patients with these mutations. [ABSTRACT FROM AUTHOR]